tiprankstipranks
Amgen, Horizon Therapeutics receive second request for additional info from FTC
The Fly

Amgen, Horizon Therapeutics receive second request for additional info from FTC

On January 30, Horizon (HZNP) and Amgen (AMGN) each received a request for additional information and documentary materials from the U.S. Federal Trade Commission in connection with the FTC’s review of Amgen’s proposed acquisition of Horizon. The effect of the Second Request is to extend the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended until 30 days after Horizon and Amgen have substantially complied with the Second Request, unless that period is extended voluntarily by the parties or terminated sooner by the FTC. Both parties intend to promptly respond to the Second Request and to continue to work cooperatively with the FTC in its review of the Transaction. Completion of the Transaction remains subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction or waiver of the other closing conditions specified in the Transaction Agreement, dated December 11, 2022, by and among Amgen, Pillartree Limited, a wholly owned subsidiary of Amgen, and Horizon.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on AMGN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles